In the quiet arithmetic of markets, Tandem Diabetes Care has arrived at a rare and telling moment: a company whose operational story — record sales, narrowing losses, steady guidance — has begun to outrun the market's willingness to believe it. The stock has nearly doubled in a year, yet analysts suggest the repricing is still incomplete, with fair value sitting some 23% above current levels. This is the familiar human drama of trust being rebuilt slowly, quarter by quarter, after years of disappointment.